Introduction
IBD
PATHOGENESIS, INFLAMMATORY BOWEL DISEASE
The global prevalence of inflammatory bowel disease (IBD) is rising, affecting over 6 million people [Commonly used medical therapies include aminosalicylates (eg, sulfasalazine and mesalamine), systemic corticosteroids, immunosuppressive agents (eg, azathioprine and methotrexate), antibacterial agents, and biologic agents (eg, adalimumab, infliximab, certolizumab, vedolizumab, and ustekinumab) [Interleukin (IL)-23 is a proinflammatory cytokine involved in the maintenance of T helper type 17 (Th17) cells, which can contribute to the pathogenesis of CD [Brazikumab is a human immunoglobulin G2 monoclonal antibody that selectively binds the p19 subunit of IL-23 [